Obezitenin Medikal Tedavisi

Obezite kompleks ve multifaktöriyel bir hastalıktır. Obezite prevalansı dünya çapında çocuk ve ergenler arasında yükselirken, etkili ve sürdürülebilir tedavilere olan talep artmaktadır. Obezitenin önemli bir kısmı morbiditeyle ilişkilidir. Obezitenin tedavisinde temel olan tıbbi beslenme tedavisi, egzersiz gibi yaşam tarzı değişikliğidir. Yaşam tarzı değişikliği önerileri yetersiz kaldığında farmakolojik tedaviler kullanılabilir. Şu anki medikal tedavilerde Orlistat tümüyle yeterli değildir. Obezite tedavisinde, yeni ilaçların geliştirilmesi hem sistemik farmakoterapinin karmaşıklığı hem de etnik köken ve yaş gibi değişkenler nedeniyle zor olsada çalışması devam eden ilaçlar mevcuttur. Güvenlik ve uzun vadeli etkinlikleri ispat edilirse, obezite yönetiminde umut verici değişiklikler beklenmektedir.

Medical Treatment of Obesity

Obesity is a complex and multifactorial disease. Together with the increasing prevalence of obesity worldwide among children and adolescents, the need for effective and sustainable treatment has been increasing. An important part of obesity is related to morbidity. Main part of the management of obesity is lifestyle change such as exercise and medical nutrition therapy. Pharmacological treatments can be used, if lifestyle modification recom-mendations are inadequate. Orlistat is not solely sufficient among the current medical treatments. Although the development of new drugs is difficult due to complexity of systemic pharmacotherapies and variables such as ethnicity and age, several drugs are still under development. If safety and long-term effectiveness of these drugs will be proven, promising changes in obesity management are expected.

___

  • Türkiye Endokrinoloji ve Metabolizma Derneği, (2018). Obezite Tanı ve Tedavi Kılavuzu ISBN: 978-605-4011-31-5. 80-6.
  • Department of Health–Public Health. Obesity general information, 2011. www.dh.gov.uk/en/Publichealth/Obesity/DH_078098. [Accessed 9 February 2012].
  • Hurt RT, Frazier TH, Mc Clave SA, et al. Obe-sity epidemic. J Parenter Enteral Nutr 2011; 35: 4-13.
  • Bray GA, Tartaglia LA, Bray GA, et al. Medi-cinal strategies in the treatment of obesity. Na-ture 2000; 404: 672.
  • Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123-8.
  • US FDA. Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events.2010. http://www.fda.gov/safety/medwatch/safety in-formation/safety alerts for human medical pro-ducts/ucm228830.htm.
  • Padwal RS, Rucker D, Li SK et al. Long-term pharmacotherapy for obesity and overweight (Review). Cochrane Database of Systematic Reviews 2003, CD004094.
  • Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-42.
  • Tonstad S, Pometta D, Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, or-listat, on serum lipids and lipoproteins in pati-ents with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46: 405-10.
  • Singh A, Sarkar SR, Gaber LW, Perazella MA. Acute oxalate nephropathy associated with or-listat, a gastrointestinal lipase inhibitor. Am J Kidney Dis 2007; 49: 153-7.
  • Smith SR, Prosser WA, Donahue DJ, et al. APD356004 Study Group. Lorcaserin (APD356), a selective 5-HT(2C) agonist, redu-ces body weight in obese men and women. Obe-sity (Silver Spring) 2009; 17: 494-503.
  • Smith SR, Weissman NJ, Anderson CM, et al; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight mana-gement. N Engl J Med 2010; 363: 245-56.
  • Fidler MC, Sanchez M, Raether B, et al. BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96: 3067-77.
  • FDA Highlights of Prescribing Information: BELVIQ (lorcaserin hydrochloride) tablets, for oral use. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf.
  • Cercato C, Roizenblatt VA, Leança CC, et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of di-ethylpropion in the treatment of obese subjects. Int J Obes 2009; 33: 857-65.
  • Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and as-sociated comorbidities in overweight and obese aduts (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-52.
  • Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012; 20: 330-42.
  • http://www.fda.gov/downloads/Drugs/DrugSafety/Postmarket Drug Safety Information for Pati-ents and Providers/UCM312598.pdf.
  • Kennett GA, Clifton PG. New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol Biochem Behav 2010; 97: 63-83.
  • Kopelman P, Bryson A, Hickling R et al. Ceti-listat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes Relat Metab Disord 2007; 31: 494-9.
  • Cheung BM, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. Ther Adv Drug Saf 2013; 4: 171-81.
  • Questions and Answers about FDA’s Initiative Against Contaminated Weight Loss Pro-ductshttp://www.fda.gov/drugs/resourcesforyou/con sumers/questionsanswers/ucm136187. Htm.
  • Kopelman P, Bryson A, Hickling R, et al. Ceti-listat (ATL962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes 2007; 31: 494-9.
  • Bryson A, De la Motte S, Dunk C. Reduction of dietary fat absorption by the novel gastrointesti-nal lipase inhibitor cetilistat in healthy volunte-ers. Br J Clin Pharmacol 2009; 67: 309-15.
  • Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic cont-rol and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2011; 13: 169-80.
  • Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 1568-75.
  • Fehm HL, Smolnik R, Kern W, et al. The mela-nocortin melanocyte-stimulating hormo-ne/adrenocorticotropin (4-10) decreases body fat in humans. J Clin Endocrinol Metab 2001; 86: 1144-8.
  • Wynne K, Park AJ, Small CJ, et al. Subcutane-ous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005; 54: 2390-5.
  • Patel PN, Pathak R. Rimonabant: a novel selec-tive cannabinoid-1 receptor antagonist for tre-atment of obesity. Am J Health Syst Pharm 2007; 64: 481-9.
  • Van Gaal L, Pi-Sunyer X, Despres JP, et al. Efficacy and safety of rimonabant for improve-ment of multiple cardiometabolic risk factors in overweight/ obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008; 3: 229-40.